About
Axel Bolte is Chief Executive Officer of Altimis Bio LLC. He co-founded Inozyme Pharma (INZY), a Nasdaq-listed rare disease company focused on treatments for metabolic diseases, where he served as director and previously as President and CEO. His background includes board roles in private and public companies and a prior career in private equity investing in healthcare companies internationally.
Founder at Inozyme Pharma
Intro paths
→
In turn, Axel can intro founders to Inozyme Pharma's investors below.
Experience
- Altimis Bio LLCChief Executive Officercurrent2026 — presentBoston, Massachusetts, United States
- Opna BioDirectorcurrent2024 — presentSan Francisco, California, United States
- Burka Coffee Estates Ltd.Directorcurrent2003 — presentTanzania
- Mondul Coffee Estates Ltd.Directorcurrent2003 — presentMonduli, Arusha, Tanzania
- Inozyme PharmaCo-Founder2023 — 2025Boston, Massachusetts, United States
- Inozyme PharmaChief Executive Officer2017 — 2023Greater Boston
- Turos Capital AGCo-Founder2018 — 2023Zurich, Switzerland
- IVERIC bioDirector2019 — 2023New York City Metropolitan Area
- Tripex Pharmaceuticals LLCManaging Member2015 — 2021San Diego County, California, United States
- HBM Partners AGVenture Partner2017 — 2019Zug
- HBM Partners AGInvestment Advisor2013 — 2017Zurich, Switzerland
- Allena Pharmaceuticals, Inc.Board Member2014 — 2019Newton, MA
- Nabriva Therapeutics plcDirector2006 — 2019Vienna
- Ophthotech CorpDirector2007 — 2019New York City Metropolitan Area
- AnaptysBioBoard Observer2015 — 2017San Diego County, California, United States
- Kolltan Pharmaceuticals, Inc.Vice Chairman of the Board2008 — 2016New Haven, CT
- PTC Therapeutics (PTCT)Director2003 — 2014New York City Metropolitan Area
- The Trout GroupUS Investment Advisor to HBM Partners2008 — 2013New York City Metropolitan Area
- Enanta PharmaceuticalsBoard Observer2005 — 2013Greater Boston
- Mpex PharmaceuticalsDirector2006 — 2011San Diego County, California, United States
- HBM Partners AGInvestment Advisor2003 — 2008Zurich, Switzerland
- Newron Pharmaceuticals SpaDirector2005 — 2008Milan, Lombardy, Italy
Skills & more
Team LeadershipNegotiation4Strategy10Board LevelMergers & Acquisitions (M&A)Due Diligence16Executive CompensationBiotechnology49Venture Financing7Drug Development23Pharmaceutical Industry24Drug Discovery27
+12 more
Medicinal ChemistryExecutive PayVenture CapitalInfectious DiseasesLifesciencesPharmacologyMergers & AcquisitionsClinical DevelopmentTechnology TransferIPOBiopharmaceuticalsClinical TrialsLanguages English · French · German · Spanish
From Axel's professional profile.
Frequently asked questions
- Who is Axel Bolte?
- Axel Bolte is Chief Executive Officer of Altimis Bio LLC. He co-founded Inozyme Pharma (INZY), a Nasdaq-listed rare disease company focused on treatments for metabolic diseases, where he served as director and previously as President and CEO. His background includes board roles in private and public companies and a prior career in private equity investing in healthcare companies internationally.
- Where does Axel Bolte work?
- Axel Bolte is Founder of Inozyme Pharma.
- What companies did Axel Bolte found?
- Axel Bolte founded Inozyme Pharma.
- Where did Axel Bolte go to school?
- Axel Bolte studied at ETH Zürich (Dipl. Natw. ETH, Biochemistry); University of St.Gallen (lic.oec.HSG, Business Administration and Management); University of Cambridge (Organic Chemistry).
Same school
Also attended ETH Zürich279
Bastian HasslingerInvestor at Index VenturesKJ SidberryInvestor at GV (Google Ventures)Steve VassalloInvestor at Foundation CapitalHelge DaebelPartner, Head of Water at Emerald Technology Ventures AgMaurin DaiInvestment Manager, Physical AI & Robotics at Emerald Technology Ventures AgChristoph FreiPartner, Head of Energy at Emerald Technology Ventures Ag
+ 273 more
Also attended University of St.Gallen345
Melissa DonohoeVice President at Notion CapitalMarjolaine CatilPrincipal at Newfund CapitalGülce KoçInvestment Manager at IdacapitalDominik MatykaInvestor at Cavalry VenturesKarol CieslukAssociate at TCVCarolina de AzevedoHead of Impact & ESG at Emerald Technology Ventures Ag
+ 339 more
Also attended University of Cambridge1,223
Stewart ButterfieldCo-founder of Slack and FlickrDemis HassabisCo-founder & CEO of Google DeepMindNiko BonatsosVerdict Capital founder and pre-consensus investor formerly at General CatalystGeorgia StevensonInvestor at Index VenturesHannah SealInvestor at Index VenturesLeah von SiemensPartner at Manta Ray Ventures
.png)
+ 1,217 more
